Tesu Saglik Teknolojileri A.S. (“Tesu Health“) is proud to announce that we have been honored with the Scientific and Technological Research Council of Turkey (TUBITAK) 1512-Entrepreneurship Capital Support Award for our “Development of evidence-based, prescription digital therapeutics for the treatment of prediabetic individuals” project (project ID: 2210830).
Share this article
The esteemed 1512 Entrepreneurship Support Program, which aims to foster innovation and entrepreneurship by providing capital and other resources, supports entrepreneurs at every stage of their venture, from idea inception to market entry. It is our firm belief that this recognition will provide us with invaluable resources and a platform for continued growth, helping us to transform our technology and innovation-driven business ideas into high-value enterprises that create skilled employment opportunities.
During the first call of 2021, a total of 2395 entrepreneurs submitted business ideas, and Tesu Health was among the applicants. Of these, 1114 entrepreneurs were selected to receive phase 1 support from 63 Implementing Organizations. Subsequently, the business plans of 305 entrepreneurs whose proposals were approved by the Implementing Organizations underwent rigorous evaluation within the scope of stage 2 panels organized by TÜBİTAK. Following the evaluation process, which involved experts from academia, industry, and investment, 132 entrepreneurs were deemed eligible to receive stage 2 support of up to 200,000 TL within the framework of the first call of 2021.
We are honored to be among the recipients of this prestigious award and are committed to utilizing the resources to achieve our mission of transforming healthcare through technology and innovation.
